Exhibit 99.1  Gemini Therapeutics Appoints Samuel Barone, M.D., as Chief Medical Officer

CAMBRIDGE, Mass. - April 12, 2021** - Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD) and linked ocular disorders, today announced the appointment of Samuel Barone, M.D., as Gemini's Chief Medical Officer, effective immediately.

This is the opening of the release as filed. Read the full document on SEC.gov, or read it in full on SPAC Watch with the trust, deadline and warrant terms alongside it.